Skip to content

Author

Kenji Watanabe

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Efficacy and safety of upadacitinib for Crohn's disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies.

BACKGROUND Upadacitinib is an oral Janus kinase inhibitor approved for the treatment of moderate-to-severe Crohn's disease (CD). This post hoc analysis reports the efficacy and safety of upadacitinib for CD in patients in East Asia enrolled in the phase 3 clinical trials. METHODS In two induction studies (U-EXCEL [NC...

Min-Hu Chen, Xiang Gao, Kenji Watanabe et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.